| 5. | Huhn G, Tebas P, Gallant J, et al. Strategic simplification: the efficacy and safety of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV) in treatment-experienced HIV-1 infected adults (NCT01968551). In: Program and abstracts of ID Week 2015; October 7-11, 2015; San Diego, CA. Abstract 726. |  |
|
